Eversana launches its ACTICS predictive analytics solution
ACTICS is designed to help life-science companies harness predictive analytics to streamline commercial launches. The technology uses artificial intelligence (AI) technology in a cloud-based integrated solution.
Brigham Hyde, Eversana’s president of data and analytics, told Outsourcing Pharma that advanced analytics and application of predictive modeling have transformed the life-sciences field, helping to maximize value while optimizing outcomes for patients.
“Technology has evolved from custom mathematical modelling to infrastructure and consideration of systems integration,” he remarked. “We built ACTICS for the next chapter of these systems, focused on streaming prediction and driving next best actions.”
Specifically, Hyde explained, technologies have been beneficial to pharma firms and drug development partners.
“At a high level, the role of AI is to accelerate the drug discovery process by ingesting and determining the relationships between billions of pieces of information. By mining and processing countless resources such as research papers, technologies like ACTICS can accelerate the discovery process of finding a drug to treat a novel disease or to better understand how this disease behaves,” he told OSP.
Hyde added that the technology could prove highly useful in identifying misdiagnosed or undiagnosed patients.
“Particularly in rare disease, many patients go undiagnosed. The ACTICS platform has particular strength in finding these patients and enabling better treatments for them,” he explained.
ACTICS is constructed on a data-mastering platform and cloud-based infrastructure, making use of integrated data. According to Eversana, it offers the ability to combine multiple data sources into a comprehensive system.
Hyde told us the ACTICS solution is intended to help pharmaceutical companies and their partners to overcome a range of obstacles encountered on the path to product launch.
“From complex therapies with multiple indications to the demand for real-world evidence, these challenges have led to life sciences companies increasingly relying on data-driven insights and advanced analytical models such as ACTICS for improved decision-making. In market access, the ability to connect payer dynamics to prescriber behavior and drive improved targeting, contracting, and forecasting at launch are all critical elements of ACTICS,” he said.
